1987 Volume 28 Issue 4 Pages 534-540
In this paper the therapeutic effects on 51 patients with hypoplastic leukemia were analyzed in order to establish the optimal clinical management of hypoplastic leukemia. Among 44 patients, hospitalized before 1984, 27 patients were treated with blood transfusion and/or single antileukemic agent, and 17 patients treated with combination chemotherapeutic regimens. As results, only 8, of which 7 patients were received combination chemotherapy, obtained CR and ages of responders were all below 65 years old. On the other hand, among 7 patients treated with low dose behenoyl cytosine arabinoside (LD-BHAC) therapy, applied since 1984, 3 patients obtained CR and 2 patients obtained PR. Responders were aged over 65 years old. Although hematologic toxicities were found during LD-BHAC therapy, they were all controllable. As conclusion, LD-BHAC therapy is thought to be a promising remission induction chemotherapy for aged patients with hypoplastic leukemia.
